Dr. Ariel Ortiz — AO monogramDr. Ariel Ortiz®

Education Center · Comparison Guide

Gastric Sleeve vs. Gastric Bypass

Two operations, one decision. This guide compares the two most-performed bariatric procedures in the world — indications, mechanism, outcomes, safety, and revision — grounded in the OCC–UCSD review of 19,801 consecutive patients with a 30-day morbidity of 1.2% and zero mortalities.

Author & medical reviewer

Written and clinically reviewed by Ariel Ortiz Lagardere, MD, FACS, FASMBS — Founder & Medical Director, Obesity Control Center®; Professor of Surgery, UABC.

Last reviewed: January 2026. Educational content only — see medical review policy and disclosures.

Side-by-side comparison

DimensionSleeve GastrectomyRoux-en-Y Gastric Bypass
Anatomy changedStomach reduced by ~75–80%; pylorus preservedSmall gastric pouch + Roux limb rerouting the small bowel
MechanismRestriction + ghrelin reductionRestriction + malabsorption + strong incretin (GLP-1/PYY) effect
Typical 1-yr weight loss~25–30% total body weight~30–35% total body weight
Type 2 diabetes remissionGood, delayedFaster, more durable at 5 years
GERD / refluxMay worsen; caution if pre-existingUsually improves reflux
Nutritional riskLower (B12, iron)Higher (iron, calcium, B12, protein) — lifelong supplementation
ReversibilityNot reversible; convertible to bypass or DSNot practically reversible
OR time (experienced team)~45–75 min~90–120 min
30-day morbidity (OCC series)≈1%≈1.5%
Best first candidateBMI 30–45, minimal reflux, first operationSevere T2D, higher BMI, significant reflux, or revision

Ranges are population estimates from peer-reviewed literature and the OCC–UCSD 19,801-patient series (2000–2021). Individual results vary and should be discussed with your surgeon.

When Dr. Ortiz recommends each operation

Sleeve gastrectomy — first-line for most

For patients with a BMI in the 30–45 range, no significant reflux, and no severe metabolic disease, sleeve gastrectomy is usually the first operation offered. It is anatomically simpler, has a shorter operative time, a slightly lower short-term complication rate, and preserves the option to convert to bypass or duodenal switch later if needed.

Gastric bypass — when metabolic disease leads

For patients with poorly controlled type 2 diabetes, significant GERD, a BMI above 45, or a history of failed sleeve, Roux-en-Y bypass is typically the better answer. Its hormonal (GLP-1/PYY) mechanism drives faster, more durable diabetes remission and reliably improves reflux.

Frequently asked questions

Which is safer, sleeve or bypass?
In the OCC–UCSD review of 19,801 consecutive bariatric procedures (2000–2021), 30-day morbidity was 1.2% with zero mortalities across sleeve and bypass, when performed in a high-volume Center of Excellence with standardized ERAS protocols. Sleeve gastrectomy carries a modestly lower short-term complication profile at population level, but in experienced hands both are exceptionally safe.
Which produces more weight loss?
Roux-en-Y gastric bypass generally produces slightly greater and more durable total body weight loss at 5–10 years, particularly in patients with higher BMI or significant metabolic disease. Sleeve gastrectomy achieves outcomes within a few percentage points at 1–2 years and is often the preferred first operation for straightforward candidates.
Which is better for type 2 diabetes?
Gastric bypass has a stronger evidence base for early and durable type 2 diabetes remission because of its hormonal (incretin) effects beyond restriction. Sleeve gastrectomy also improves diabetes meaningfully, but bypass is usually preferred when diabetes is the dominant indication.
Which is easier to revise?
Sleeve gastrectomy is generally easier to convert if weight regain or reflux develops — most commonly to bypass or duodenal switch. Bypass revisions are technically more complex and less commonly performed.
How do GLP-1 medications change this decision?
GLP-1 therapy (semaglutide, tirzepatide) does not replace surgery for severe obesity, but it can augment surgical outcomes, treat regain, and delay surgery in selected patients. The choice between sleeve and bypass is now made inside a broader medication + surgery + follow-up plan.

Continue in the Education Center or read Dr. Ortiz's analysis of the GLP-1 era. For a professional consultation, please get in touch.